Targeted pill to keep leukemia from returning after a stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new targeted pill (a menin inhibitor) taken after a stem cell transplant to help keep AML from coming back. It's for people with certain genetic markers in their leukemia who are already planning a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML) that is in complete remission (no visible leukemia).
- Your leukemia cells have a specific genetic change: KMT2A rearrangement, NPM1 mutation, or NUP98 rearrangement.
- You are scheduled to receive a stem cell transplant (from a related or unrelated donor, including half-matched donors).
- You are generally healthy enough for a transplant, with adequate heart, lung, kidney, and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called revumenib to help keep leukemia from coming back after a stem cell transplant. It is for people with specific genetic types of acute leukemia who have recently had or will soon have a transplant.
This trial tests revumenib, a targeted medicine, to treat acute leukemia that has come back or hasn’t fully gone away. It may help people whose leukemia has specific gene changes (like KMT2A or NPM1) by trying to better control the cancer.
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a new drug called revumenib combined with a strong chemotherapy regimen (7+3) and midostaurin for people with newly diagnosed AML that has specific gene mutations (FLT3 and NPM1). The goal is to see if this combination works better than standard treatments.
This study looks at how a new drug called a menin inhibitor works in patients with acute myeloid leukemia (a blood cancer) who have relapsed after receiving a stem cell transplant. Researchers want to understand which patients benefit most by studying specific markers in their blood.
Hear when a new Relapsed Adult AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.